Aurora Cannabis Inc (ACB) reports significant revenue increases and maintains a robust cash position, despite challenges in ...

Despite reporting better-than-expected revenue for Q1 fiscal 2026, Aurora Cannabis (NASDAQ:ACB) traded ~9% lower after the ...

ACB's global medical cannabis momentum stays strong, but near-term regulatory headwinds might have limited Q1 revenue upside.

Q1 2026 Earnings Call Transcript August 6, 2025 Aurora Cannabis Inc. misses on earnings expectations. Reported EPS is $-0.19 ...

Aurora Cannabis Inc. closed 37.78% short of its 52-week high of $7.20, which the company reached on August 15th.

Aurora Cannabis Inc. ( NASDAQ: ACB) Q1 2026 Earnings Conference Call August 6, 2025 8:00 AM ET Kevin Niland - Corporate Participant Miguel Martin - CEO & Executive Chairman Simona King - Chief ...

Aurora Cannabis Inc. shares T.ACB are trading down $0.37 at $5.97.

Aurora said it anticipates revenue will increase year over year in the second fiscal quarter, supported by between 8% and 12% growth in its global medical cannabis segment. Plant propagation revenue ...

In Europe, solid growth in Germany likely drove fiscal first-quarter revenue, supported by cannabis de-scheduling and more ...

Poll: Marijuana consumers expect federal legalization by 2028; Study: Legal dispensaries tied to reduced opioid deaths; Ohio legal sales anniversary Subscribe to receive Marijuana Moment’s newsletter ...

Author:Shweta Raskar, Business Development Specialist, Prophecy Market InsightsIntroductionThe Europe Legal Cannabis Market ...